AU2010220396B2 - Phosphate adsorbent - Google Patents

Phosphate adsorbent Download PDF

Info

Publication number
AU2010220396B2
AU2010220396B2 AU2010220396A AU2010220396A AU2010220396B2 AU 2010220396 B2 AU2010220396 B2 AU 2010220396B2 AU 2010220396 A AU2010220396 A AU 2010220396A AU 2010220396 A AU2010220396 A AU 2010220396A AU 2010220396 B2 AU2010220396 B2 AU 2010220396B2
Authority
AU
Australia
Prior art keywords
iron
calcium
magnesium
composition
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010220396A
Other languages
English (en)
Other versions
AU2010220396A1 (en
Inventor
Peter Geisser
Erik Philipp
Gisela Witzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vifor International AG
Original Assignee
Vifor International AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40627528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010220396(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor International AG filed Critical Vifor International AG
Publication of AU2010220396A1 publication Critical patent/AU2010220396A1/en
Application granted granted Critical
Publication of AU2010220396B2 publication Critical patent/AU2010220396B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010220396A 2009-03-02 2010-03-01 Phosphate adsorbent Ceased AU2010220396B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09154107.8 2009-03-02
EP09154107 2009-03-02
PCT/EP2010/052551 WO2010100112A1 (en) 2009-03-02 2010-03-01 Phosphate adsorbent

Publications (2)

Publication Number Publication Date
AU2010220396A1 AU2010220396A1 (en) 2011-09-01
AU2010220396B2 true AU2010220396B2 (en) 2013-10-17

Family

ID=40627528

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010220396A Ceased AU2010220396B2 (en) 2009-03-02 2010-03-01 Phosphate adsorbent

Country Status (20)

Country Link
US (1) US20120052135A1 (enExample)
EP (1) EP2403506A1 (enExample)
JP (1) JP2012519201A (enExample)
KR (1) KR101497003B1 (enExample)
CN (1) CN102341111A (enExample)
AR (1) AR076070A1 (enExample)
AU (1) AU2010220396B2 (enExample)
BR (1) BRPI1009110A2 (enExample)
CA (1) CA2753364A1 (enExample)
CL (1) CL2011002130A1 (enExample)
IL (1) IL214509A0 (enExample)
MX (1) MX2011009144A (enExample)
MY (1) MY162484A (enExample)
NZ (1) NZ594730A (enExample)
PE (1) PE20120327A1 (enExample)
RU (1) RU2527682C2 (enExample)
SG (1) SG173887A1 (enExample)
TW (1) TWI454267B (enExample)
WO (1) WO2010100112A1 (enExample)
ZA (1) ZA201106305B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0913525D0 (en) * 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
EP2548562A1 (de) 2011-07-18 2013-01-23 SeBo GmbH Kombinationstherapie mit Eisen-basierenden Phosphatadsorbern
CN109497565B (zh) * 2013-03-08 2021-10-26 上海礼邦医药科技有限公司 金属离子-功能性纤维组分络合物组合物、其制备及用途
EP2805603B1 (de) * 2013-05-22 2017-01-11 CLAAS E-Systems KGaA mbH & Co KG Vorrichtung und Verfahren zur Überwachung der Schneidenschärfe
WO2015181205A1 (en) 2014-05-28 2015-12-03 Biaqua B.V. Method for removing phosphate from water fractions
CN105232767A (zh) * 2015-09-29 2016-01-13 江苏锦宇环境工程有限公司 一种制备吸附磷酸盐的药物制剂的方法
CN107397758A (zh) * 2016-05-19 2017-11-28 欣凯医药化工中间体（上海）有限公司 一种磷结合剂及其制备方法
CN107397760B (zh) * 2016-05-19 2021-07-30 欣凯医药化工中间体（上海）有限公司 基于铁的氢氧化物－低分子量糖的磷结合剂、其制备方法及其应用
CA3063424A1 (en) 2017-05-31 2018-12-06 Mars, Incorporated Methods of diagnosing and treating chronic kidney disease
SI3930686T1 (sl) 2019-02-28 2023-11-30 Renibus Therapeutics, Inc. Novi železovi sestavki ter metode njihove izdelave in uporabe
US20210130251A1 (en) * 2019-07-17 2021-05-06 Water Warriors Inc. Adsorbent Structures for the Removal of Phosphates and Ammonia from Wastewater and Methods of Use
JP2022541593A (ja) * 2019-07-23 2022-09-26 ソシエテ・デ・プロデュイ・ネスレ・エス・アー ネコ科動物の腎臓に有益な方法及び組成物
CN113029978A (zh) * 2019-12-25 2021-06-25 远大生命科学(辽宁)有限公司 一种检测含镧试剂的磷结合能力的方法
CN111905736B (zh) * 2020-07-23 2021-10-26 安徽工业大学 一种半胱氨酸功能化改性的羟基氧化铁、电催化剂、制备方法及应用
WO2025176793A1 (en) * 2024-02-21 2025-08-28 Mars, Incorporated Food composition for treating mineral bone disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970079A (en) * 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
US6174442B1 (en) * 1995-12-19 2001-01-16 Vifor (International) Ag Adsorbent for phosphate from an aqueous medium, production and use of said adsorbent
US20040105896A1 (en) * 1997-09-19 2004-06-03 Crosfield Limited Metal compunds, mixed or sulphated, as phosphate binders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19917705C1 (de) * 1999-04-20 2000-12-28 Vitasyn Gmbh Mittel zur Therapie von Hyperphosphatämie
DE102004031181A1 (de) * 2004-06-28 2006-01-19 Vifor (International) Ag Phosphatadsorbens
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
DK2319804T3 (en) * 2006-12-14 2015-01-19 Novartis Ag Iron (III) -carbohydrat-based phosphatadsorbens

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970079A (en) * 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
US6174442B1 (en) * 1995-12-19 2001-01-16 Vifor (International) Ag Adsorbent for phosphate from an aqueous medium, production and use of said adsorbent
US20040105896A1 (en) * 1997-09-19 2004-06-03 Crosfield Limited Metal compunds, mixed or sulphated, as phosphate binders

Also Published As

Publication number Publication date
WO2010100112A1 (en) 2010-09-10
NZ594730A (en) 2013-06-28
RU2011140017A (ru) 2013-04-10
IL214509A0 (en) 2011-09-27
CN102341111A (zh) 2012-02-01
RU2527682C2 (ru) 2014-09-10
CA2753364A1 (en) 2010-09-10
KR101497003B1 (ko) 2015-02-27
AR076070A1 (es) 2011-05-18
ZA201106305B (en) 2012-05-30
MX2011009144A (es) 2011-09-15
TWI454267B (zh) 2014-10-01
SG173887A1 (en) 2011-10-28
US20120052135A1 (en) 2012-03-01
PE20120327A1 (es) 2012-04-11
KR20110128329A (ko) 2011-11-29
TW201034677A (en) 2010-10-01
CL2011002130A1 (es) 2012-03-23
AU2010220396A1 (en) 2011-09-01
EP2403506A1 (en) 2012-01-11
MY162484A (en) 2017-06-15
BRPI1009110A2 (pt) 2019-09-24
JP2012519201A (ja) 2012-08-23

Similar Documents

Publication Publication Date Title
US20120052135A1 (en) Phosphate Adsorbent
Trailokya et al. Calcium and calcium salts
US8728533B2 (en) Composition comprising crustacean gastrolith components and its use
US20060134227A1 (en) Compositions including iron
ES2895044T3 (es) Suplemento de hierro
CA2376017C (en) Potassium calcium citrate compositions and methods for production
KR20020006114A (ko) 체내에 흡수되기 용이한 단백화-아연의 제조방법
Loghman-Adham Phosphate binders for control of phosphate retention in chronic renal failure
US20040048925A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
WO2007011740A2 (en) A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis
Funk et al. Interactions Between Iron (III)-hydroxide Polymaltose Complex and Commonly Used Medications
US20040220266A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US7862836B2 (en) Phosphorus binder for treatment of kidney disease
JPH0586932B2 (enExample)
WO2017198199A1 (zh) 基于铁的氢氧化物－低分子量糖的磷结合剂、其制备方法及其应用
US8034833B2 (en) Phosphorus binder for treatment of renal disease
EP1750527A1 (en) Compositions and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
Harmse Understanding the management of iron deficiency anaemia
Harmse Understanding the management of iron deficiency anaemia
Khanwelkar et al. CONVENTIONAL AND NEWER ORAL IRON PREPARATIONS
Schlussel Mineral Absorption and deficiency
HK1116672A (en) Compositions including iron

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired